 However, at their current price, it's not a cost-effective solution for insurance companies in the United States, whether they're in the government sector like Medicare or Medicaid, or for that matter in the commercial sector, for most of them or many of them to cover these drugs because they're effectively too expensive. And the list price, of course, is different from the net price. There's no question about that.